Reviewing Eloxx Pharmaceuticals Inc. (ELOX)’s and Omeros Corporation (NASDAQ:OMER)’s results

Both Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) and Omeros Corporation (NASDAQ:OMER) are each other’s competitor in the Biotechnology industry. Thus the compare of their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eloxx Pharmaceuticals Inc. N/A 0.00 44.51M -1.64 0.00
Omeros Corporation 21.61M 30.64 119.77M -2.48 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 has Eloxx Pharmaceuticals Inc. and Omeros Corporation’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Eloxx Pharmaceuticals Inc. 0.00% 0% 0%
Omeros Corporation -554.23% 270.2% -123.7%

Risk and Volatility

Eloxx Pharmaceuticals Inc.’s volatility measures that it’s 84.00% more volatile than S&P 500 due to its 1.84 beta. Omeros Corporation on the other hand, has 3.71 beta which makes it 271.00% more volatile compared to S&P 500.


The Current Ratio and a Quick Ratio of Eloxx Pharmaceuticals Inc. are 11.1 and 11.1. Competitively, Omeros Corporation has 2.7 and 2.7 for Current and Quick Ratio. Eloxx Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Omeros Corporation.

Insider and Institutional Ownership

The shares of both Eloxx Pharmaceuticals Inc. and Omeros Corporation are owned by institutional investors at 52.2% and 48% respectively. Insiders owned roughly 0.4% of Eloxx Pharmaceuticals Inc.’s shares. Comparatively, insiders own roughly 0.4% of Omeros Corporation’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Eloxx Pharmaceuticals Inc. -14.32% -6.06% -22.12% -29.94% 75.53% 66.75%
Omeros Corporation -0.72% -15.24% -46.46% -25.18% -31.27% -28.72%

For the past year Eloxx Pharmaceuticals Inc. has 66.75% stronger performance while Omeros Corporation has -28.72% weaker performance.


On 6 of the 9 factors Eloxx Pharmaceuticals Inc. beats Omeros Corporation.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use during cataract surgery or intraocular lens replacement. Its clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases. The companyÂ’s clinical programs also consists of OMS824, which is in Phase II clinical trial for the treatment of Huntington's diseases and schizophrenia; OMS405 that is in Phase II clinical trial to treat opioid and nicotine addiction; and OMS201, which is in Phase I/II clinical trial for use during urological procedures. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; OMS721 for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and OMS616 to control surgical and traumatic bleeding. The companyÂ’s preclinical programs also include GPR17 for the treatment of myelin formation; GPR101 for appetite and eating disorders; GPR151 to treat schizophrenia and cognition; GPR161 for triple-negative breast cancer treatment; GPR183 for the treatment of osteoporosis, and Epstein-Barr virus infections and related diseases; GPR174 for modulation of the immune system; and Antibody Platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. In addition, the company is developing OMS103 that has completed Phase III clinical trial for arthroscopic anterior cruciate ligament reconstruction and arthroscopic partial meniscectomy. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.